Does consumer demand pull scientifically novel drug innovation?

Abstract

Prior literature shows that stronger consumer demand leads to increased pharmaceutical R&D. However, how strong these “demand‐pull” effects are for more scientifically novel drug innovation remains unknown. We address this question using comprehensive clinical trial data that include precise characterizations of the scientific approaches used in tested molecules. We characterize scientific novelty as the number of times each approach has been used in the past. Exploiting exogenous demand variation introduced by the introduction of Medicare Part D, we find strong evidence that demand‐pull effects are markedly skewed in favor of non‐novel or “follow‐on” drug R&D.

Research and market structure: Evidence from an antibiotic-resistant pathogenic outbreak

“…It is not surprising that shocks to research will impact future development activities or that development shocks will impact product markets (e.g., Byrsiki et al, 2021). Nor is it surprising that product market shocks impact development activities (e.g., Agarwal and Gaule, 2021;Manso et al, 2019;Branstetter et al, 2014;Blume-Kohout and Sood, 2013;Dranove et al, 2021;Dubois et al, 2013;Acemoglu and Linn, 2004;Finkelstein, 2004). In these literatures, however, events are occurring between connected parts of the R&D process.…”

Innovation and profitability following antitrust intervention against a dominant platform: The wild, wild west?

“…20 20 We plot event study charts following the template of Dranove, Garthwaite, and Hermosilla (2021) in figure A2. The pattern for low‐share firms mirrors that seen in the full sample: coefficients are statistically insignificant prior to treatment and only diverge from 0 after treatment, as expected.…”